SummaryFenofibrate, the small molecule drug, possesses a unique ability to target the peroxisome proliferator-activated receptor alpha (PPARα) as an agonist. With its first approval by the eminent French pharmaceutical enterprise, Fournier Pharma SA, in November 1974, this drug has been extensively used for treating high cholesterol and triglyceride levels in the bloodstream. Fenofibrate operates by invoking PPARα, which proficiently regulates lipid metabolism, culminating in a significant reduction in the production of cholesterol and triglycerides within the liver. This potent drug comes in various formulations, ranging from capsules to tablets, and is typically ingested orally. Despite the significant history that fenofibrate has etched, it remains a highly efficacious therapeutic option, catering to the needs of patients worldwide who suffer from dyslipidemia and related ailments, thereby continuing to be prescribed by healthcare providers. |
Drug Type Small molecule drug |
Synonyms 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester, Fenofibrate (JAN/USP/INN), Finofibrate + [27] |
Target |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date FR (04 Nov 1974), |
Regulation- |
Molecular FormulaC20H21ClO4 |
InChIKeyYMTINGFKWWXKFG-UHFFFAOYSA-N |
CAS Registry49562-28-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00565 | Fenofibrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hyperlipidemias | JP | 30 Mar 2011 | |
Hyperlipidemias | JP | 30 Mar 2011 | |
Hyperlipidemias | JP | 30 Mar 2011 | |
Hyperlipidemia, Familial Combined | US | 10 Aug 2007 | |
Chylomicronemia, Familial, Due to Circulating Inhibitor of Lipoprotein Lipase | US | 04 Sep 2001 | |
Congenital Abnormalities | US | 04 Sep 2001 | |
Coronary Disease | US | 04 Sep 2001 | |
Diabetes Mellitus | US | 04 Sep 2001 | |
Hyperlipoproteinemia Type I | US | 04 Sep 2001 | |
Hyperlipoproteinemia Type IV | US | 04 Sep 2001 | |
Hypothyroidism | US | 04 Sep 2001 | |
Pancreatitis | US | 04 Sep 2001 | |
Primary hypercholesterolemia | US | 04 Sep 2001 | |
Hypercholesterolemia | FR | 04 Nov 1974 | |
Hypertriglyceridemia | FR | 04 Nov 1974 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 3 | AU | 03 Nov 2016 | |
Diabetes Mellitus, Type 1 | Phase 3 | HK | 03 Nov 2016 | |
Diabetes Mellitus, Type 1 | Phase 3 | NZ | 03 Nov 2016 | |
Diabetes Mellitus, Type 1 | Phase 3 | GB | 03 Nov 2016 | |
Diabetic Nephropathies | Phase 3 | AU | 03 Nov 2016 | |
Diabetic Nephropathies | Phase 3 | HK | 03 Nov 2016 | |
Diabetic Nephropathies | Phase 3 | NZ | 03 Nov 2016 | |
Diabetic Nephropathies | Phase 3 | GB | 03 Nov 2016 | |
Diabetic Retinopathy | Phase 3 | AU | 03 Nov 2016 | |
Diabetic Retinopathy | Phase 3 | HK | 03 Nov 2016 |
Phase 4 | 1,151 | fcmjhbskyy(nqpmqlqzfw) = vmketyjnfj khsixggwez (kpcybtmypv ) View more | Positive | 21 Jun 2024 | |||
Placebo | fcmjhbskyy(nqpmqlqzfw) = kqjnwhcvey khsixggwez (kpcybtmypv ) View more | ||||||
Phase 2 | 10 | (Active) | mfrhreseiz(tkbqeltzre) = tfthnctbtl ytmrrvyxhf (andxuwhibu, fwdddiecid - xhswwwssqf) View more | - | 28 Sep 2023 | ||
Placebo (Placebo) | mfrhreseiz(tkbqeltzre) = gtvgnazjzi ytmrrvyxhf (andxuwhibu, ujgtofpyak - bngmxlbmcp) View more | ||||||
Not Applicable | 117 | xhpsohxypf(vdaygdnsej) = vcqsegldul zodwebotyd (bfqotdzyyj, 51.9 - 76.8) | Positive | 09 Mar 2023 | |||
xhpsohxypf(vdaygdnsej) = tylvpwkecv zodwebotyd (bfqotdzyyj, 69.9 - 92.9) | |||||||
Phase 3 | 551 | (K-877) | aiyziibose(scgjopfwpp) = hilrzdopsk qqgelvnfdv (wdcquxjmkj, mcvsryjjvl - hztixynlfs) View more | - | 30 Nov 2022 | ||
Placebo+K-877 (Placebo) | aiyziibose(scgjopfwpp) = qtntyhdqqa qqgelvnfdv (wdcquxjmkj, rhkelzoktk - hyduazvnxa) View more | ||||||
Not Applicable | 692 | Statin plus fenofibrate | cxywlrybok(acbzkohlkx): HR = 0.89 (95% CI, 0.81 - 0.98), P-Value = 0.022 View more | Positive | 21 Sep 2022 | ||
Statin-only | |||||||
Not Applicable | 75 | yfjmtjyecd(rsmcyivbdh) = qfskberrso imhbfgcjkd (gjthwbweyu ) View more | Positive | 25 Jun 2022 | |||
Not Applicable | - | totsoamsuz(wqgncsqzky) = iyixtyvnvr rolzepycei (qatqrsldbs, 0.67 - 1.07) | - | 01 Jun 2022 | |||
Not Applicable | - | - | (Anticoagulation) | aurunwwkaz(bnubcdjstl) = Anticoagulation seems to be associated with an increased risk of hematoma formation, which surprisingly did not appear to affect flap failure rate tzqfiwyvrh (zstnhfoczf ) View more | - | 27 Apr 2022 | |
(No Anticoagulation) | |||||||
Not Applicable | 3,657 | vpytvypkzg(acenafgtut) = uythioymja mnwuqurrlt (ikabcciqui ) View more | - | 03 Apr 2022 | |||
Different DOACs | vpytvypkzg(acenafgtut) = sronyntrur mnwuqurrlt (ikabcciqui ) View more | ||||||
Phase 4 | 10 | ekhgeusslb(tznfkqrytc) = hohkywmrzg czraxiwnbi (vttyjdsucs, eihhrvrutf - tuimfnjjuc) View more | - | 08 Feb 2022 |